GlobeImmune Inc (GBIM) formerly known as Ceres Pharmaceuticals Inc, is a biopharmaceutical company focused on the development of products that can treat cancer and infectious diseases based on their proprietary Tarmogen platform. Tarmogens activate a subset of white blood cells called T cells that have the ability to destroy infected or malignant cells. This is in contrast to traditional vaccines which predominately stimulate antibody production. GlobeImmune has developed four Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The firms products include GI-5005, a product for the treatment of chronic hepatitis C infection; and GI-4000 for pancreas, non-small cell lung, colorectal, and other cancers. In addition to this, the firm has formed strategic alliances with both Gilead Sciences Inc and Celgene. As a result of this, GlobImmune has exclusively licensed product canidates for chronic hepatitis B virus (HBV) to Gilead and the treatment of cancer to Celgene.
